Atherogenic dyslipidemia: Prevalence and management in lipid clinics;Dislipemia aterogénica: prevalencia y control en las unidades de lípidos

Revista Clinica Espanola

Volumn 214, Issue 9, 2014, Pages 491-498

  Pedro Botet, J ^a   Flores Le Roux, J A ^a   Mostaza, J M ^b   Pinto X ^c   De La Cruz, J J ^d   Banegas, J R ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Atherogenicdyslipidemia; Cardiovascular riskprevention; Epidemiology; HDL cholesterol; Lipid clinics; Triglycerides

Indexed keywords

FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OBESITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SPAIN;

EID: 84910624183     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2014.06.001     Document Type: Article

References (25)

1. J. Perk, G. de Backer, H. Gohlke, I. Graham, Z. Reiner, and M. Verschuren European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
2. J. Ascaso, P. González-Santos, A. Hernández-Mijares, A. Mangas-Rojas, L. Masana, and J. Millán Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum Am J Cardiovasc Drugs 7 2007 39 58
3. R. Gabriel, M. Alonso, A. Segura, M.J. Tormo, L.M. Artigao, J.R. Banegas ERICE Cooperative Group Prevalence, geographic distribution and geographic variability of major cardiovascular risk factors in Spain. Pooled analysis of data from population-based epidemiological studies: the ERICE Study Rev Esp Cardiol 61 2008 1030 1040
4. X. Pintó, J. Millán, A. Muñoz, E. Corbella, A. Hernández-Mijares, and M. Zuñiga A very high prevalence of low HDL cholesterol in Spanish patients with acute coronary syndromes Clin Cardiol 33 2010 418 423
5. V.J. Carey, L. Bishop, N. Laranjo, B.J. Harshfield, C. Kwiat, and F.M. Sacks Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control Am J Cardiol 106 2010 757 763
6. J. Millán Núñez-Cortés, J. Pedro-Botet, and X. Pintó Sala Riesgo vascular residual: recomendaciones de la Iniciativa Española para la Reducción del Riesgo Residual Med Clin (Barc) 135 2010 165 171
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 285 2001 2486 2497
8. I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 28 2007 2375 2414
9. D.D. Waters, C. Brotons, C.W. Chiang, J. Ferrières, J. Foody, J.W. Jukema Lipid Treatment Assessment Project 2 Investigators Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals Circulation 120 2009 28 34
10. J.R. González-Juanatey, J. Millán, E. Alegría, C. Guijarro, J.V. Lozano, and G.C. Vitale Prevalencia y características de la dislipemia en pacientes en prevención primaria y secundaria tratados con estatinas en España. Estudio DYSIS-España Rev Esp Cardiol 64 2011 286 294
11. J.R. González-Juanatey, A. Cordero, G.C. Vitale, B. González-Timón, P. Mazón, and V. Bertomeu Magnitud y características del riesgo residual lipídico en pacientes con antecedentes de revascularización coronaria: estudio ICP-Bypass Rev Esp Cardiol 64 2011 862 868
12. L. Pérez de Isla, A. Saltijeral Cerezo, G. Vitale, B. González Timón, A. Torres Do Rego, and L.A. Álvarez-Sala Walther Prevalencia de colesterol LDL inadecuado en pacientes con enfermedad coronaria y/o diabetes mellitus tipo 2 Rev Clin Esp 212 2012 475 481
13. P. Guallar-Castillón, M. Gil-Montero, L.M. León-Muñoz, A. Graciani, A. Bayán-Bravo, and J.M. Taboada Magnitud y manejo de la hipercolesterolemia en la población adulta de España, 2008-2010: el estudio ENRICA Rev Esp Cardiol 65 2012 551 558
14. J. Millán Núñez-Cortés, J. Pedro-Botet, A. Brea-Hernando, A. Díaz-Rodríguez, P. González-Santos, and A. Hernández-Mijares Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica Rev Esp Cardiol 67 2014 36 44
15. J. Pedro-Botet, J.M. Mostaza, X. Pintó, J.R. Banegas en nombre del grupo de investigadores EDICONDIS-ULISEA Consecución del objetivo terapéutico del colesterol de las lipoproteínas de baja densidad en las unidades de lípidos y riesgo vascular de la Sociedad Española de Arteriosclerosis Clin Investig Arterioscler 25 2013 155 163
16. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
17. ACCORD., Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
18. The, AIM-HIGH., Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
19. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J. 34 2013 1279 1291
20. M. Von Eynatten, A. Hamann, D. Twardella, P.P. Nawroth, H. Brenner, and D. Rothenbacher Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease Clin Chem 52 2006 853 859
21. M. Von Eynatten, A. Hamann, D. Twardella, P.P. Nawroth, H. Brenner, and D. Rothenbacher Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease Eur Heart J 29 2008 1307 1315
22. S.M. Hoy, and G.M. Keating Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia Drugs 69 2009 1077 1105
23. E. Bruckert, J. Labreuche, and P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
24. M. Jun, C. Foote, J. Lv, B. Neal, A. Patel, and S.J. Nicholls Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
25. H. Ghandehari, S. Kamal-Bahl, and N.D. Wong Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004 Am Heart J 156 2008 112 119